Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 32584996.
- Also identified by DOI 10.1093/cid/ciaa861 and PMC identifier 7958836.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
No safety concerns were identified in a randomized, crossover study of alendronate/placebo in youth with perinatal HIV infection and low bone mineral density (BMD). BMD improved with 48 weeks of alendronate and continued to improve with an additional 48 weeks of therapy. Gains were largely maintained 48 weeks after stopping alendronate.
Medical subject headings
- Bone Density Conservation Agents
- Bone Diseases, Metabolic
- HIV Infections